The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.
until further notice
SourceAids, 20, 7, (2006), pp. 1069-1071
Article / Letter to editor
Display more detailsDisplay less details
SubjectCTR 2: Clinical Pharmacology and physiology; EBP 3: Effective Primary Care and Public Health; N4i 1: Pathogenesis and modulation of inflammation; N4i 2: Invasive mycoses and compromised host; N4i 3: Poverty-related infectious diseases; NCEBP 13: Infectious diseases and international health; NCMLS 1: Immunity, infection and tissue repair; NCMLS 1: Infection and autoimmunity; UMCN 3.2: Cognitive neurosciences; UMCN 4.1: Microbial pathogenesis and host defense; CTR 2: Clinical Pharmacology and physiology
For 95 protease inhibitor-experienced HIV-1-infected patients, the genotypic inhibitory quotient (GIQ; trough level/number of mutations) was calculated for lopinavir. Three different sets of mutations showed equal predictive value. However, the use of cumulative numbers of mutations for calculation of the GIQ showed significantly better association with the virological response. Furthermore, the predictive value of the GIQ was no different from that of the number of mutations alone.
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.